Regenerative medicines specialist Tissue Regenix Group PLC (AIM:TRX, OTC:TSSNF) (LON:TRX) said it formally launched new products DermaPure Meshed and VNEW.
Both are line extensions that will be sold by the company's BioSurgery division and use the firm’s patented decellularisation or dCELL technology.
Unlike alternative processes, dCELL removes 99% of DNA and other cellular debris with virtually no structural disruption.
In doing this it allows the “optimal repair, replacement, and/or reconstruction of the damaged extracellular matrix”.
Chief executive Daniel Lee said: "We are pleased to launch two new products using our patented dCELL technology, extending our product lines and helping drive market penetration with our diversified portfolio."